Shots:

• The agreement follows the NICE recommendation to deliver Leqvio via a population health management approach for high-risk cardiovascular patients across England
• The NICE recommendation was based on Novartis’s ORION clinical research program including P- III trials ORION-9/10/11 evaluating the safety- efficacy- and tolerability of inclisiran in 3-600 patients with CVD which showed that the therapy-maintained LDL-C reduction through 6mos. dosing interval
• Inclisiran is the 1st siRNA therapy for the reduction of LDL-C levels via RNAi & is licensed in the EU for the treatment of adults with primary hypercholesterolaemia or mixed dyslipidaemia as an adjunct to diet

  Ref: Novartis | Image: Novartis